Skip to content

Noninvasive Hemoglobin Repeatability and Reproducibility in a Blood Donation Setting

Noninvasive Hemoglobin Spot Check Repeatability and Reproducibility in a Blood Donation Setting

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04490863
Enrollment
26
Registered
2020-07-29
Start date
2020-07-16
Completion date
2020-08-20
Last updated
2021-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia, Healthy

Brief summary

The primary objective of this clinical investigation is to report on the repeatability and reproducibility of SpHb measurements from Rad-67 devices and DCI Mini sensors used to screen prospective blood donors at a donation center.

Interventions

Noninvasive pulse oximeter that measures hemoglobin

Sponsors

Masimo Corporation
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* At least 18 years of age * Weight at least 110 pounds * Subjects with the intention of being screened for eligibility to donate blood * The subject has given written informed consent to participate in the study

Exclusion criteria

* Subjects with skin abnormalities at the planned application sites that may interfere with sensor application, per directions-for-use (DFU) or trans-illumination of the site, such as burns, scar tissue, infections, abnormalities, etc. * Subjects unwilling to remove nail polish or acrylic nails * Subjects with blood cancers such as leukemia * Subjects with hemoglobin disorders such as sickle-cell anemia and thalassemia or with known history of infectious diseases such as HIV/AIDS, syphilis, hepatitis, etc. * Subjects with self-disclosed/known pregnancy at the time of enrollment * Subjects deemed not suitable for the study at the discretion of the investigator * Subjects unlikely to be able to refrain from excessive motion during data collection. Excessive motion includes postural changes, making hand gestures, involuntary muscular movements, etc.

Design outcomes

Primary

MeasureTime frameDescription
Coefficient of Variation of Rad-67Approximately 90 minutes per subjectCoefficient of variation will be computed using Repeatability and Reproducibility variance.

Countries

United States

Participant flow

Participants by arm

ArmCount
Test Subjects
All subjects are enrolled and receive Rad-67 Pulse oximeter & DCI Mini sensor for measurement of hemoglobin. Rad-67 Pulse oximeter & DCI Mini sensor: Noninvasive pulse oximeter that measures hemoglobin
26
Total26

Baseline characteristics

CharacteristicTest Subjects
Age, Categorical
<=18 years
1 Participants
Age, Categorical
>=65 years
2 Participants
Age, Categorical
Between 18 and 65 years
23 Participants
Race/Ethnicity, Customized
Race
Asian
2 Participants
Race/Ethnicity, Customized
Race
Black or African American
1 Participants
Race/Ethnicity, Customized
Race
Mexican
7 Participants
Race/Ethnicity, Customized
Race
Middle Eastern
1 Participants
Race/Ethnicity, Customized
Race
More Than One Race
1 Participants
Race/Ethnicity, Customized
Race
Native Hawaiian or Other Pacific Islander
1 Participants
Race/Ethnicity, Customized
Race
Unknown or Not Reported
1 Participants
Race/Ethnicity, Customized
Race
White
12 Participants
Region of Enrollment
United States
26 participants
Sex: Female, Male
Female
15 Participants
Sex: Female, Male
Male
11 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 26
other
Total, other adverse events
0 / 26
serious
Total, serious adverse events
0 / 26

Outcome results

Primary

Coefficient of Variation of Rad-67

Coefficient of variation will be computed using Repeatability and Reproducibility variance.

Time frame: Approximately 90 minutes per subject

ArmMeasureValue (NUMBER)
Test SubjectsCoefficient of Variation of Rad-674.50 Coefficient of Variation percentage

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026